Print
26 March 2018
GMP News
The Institute of Bionic Technology and Engineering was established in March 2018 at Sechenov University’s Biomedicine Science and Technology Park.
The key objectives of the Institute include the development of artificial organs and bionic prostheses, hemocompatible anticoagulant coatings for implants, as well as tissue engineering, intelligent diagnostics, and organs on chips.
Current projects involve artificial heart, artificial kidney, anti-bacterial coatings for artificial prostheses and organs, nanocomposite coatings for implants of joint ligaments, implant nanomaterials for restoring bone and cartilage defects. In addition, the Institute will develop personalized diagnostic systems to assist decision-making in the early diagnosis of diseases.
The first stage will include the opening of two laboratories – the first one will specialize in wearable biocompatible devices and bionic prostheses; and the second, in biomedical nanotechnology. The Institute was established as part of strategic partnership with the National Research University of Electronic Technology (MIET).
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.